Cat. No. 5915
Alternative Name: PF 9613
Chemical Name: 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-
Biological ActivityPotent PDE9 inhibitor (IC50 = 22 nM). Also exhibits a high affinity for cGMP (Km ~170 nM). Brain penetrant.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Lee et al (2015) Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519 472. PMID: 25799991.
Claffey et al (2012) Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J.Med.Chem. 55 9055. PMID: 23025719.
Kleiman et al (2012) Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J.Pharmacol.Exp.Ther. 341 396. PMID: 22328573.
If you know of a relevant reference for PF 04449613 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PF 04449613 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PF 04449613, supplier, PF04449613, PF9613, phosphodiesterases, PDE, A, inhibitors, inhibits, potent, Schizophrenia, Alzheimer's, disease, brain, penetrant, Tocris Bioscience, Phosphodiesterase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and highly selective PDE5 inhibitor; orally bioavailable7-Ethoxyresorufin
Fluorometric CYP450 substrateGaleterone
CYP17 inhibitor; also androgen receptor antagonist
August 20 - 24, 2017
Paris , France